Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E17.48 EPS (ttm)3.65 Insider Own0.10% Shs Outstand1.62B Perf Week-0.48%
Market Cap103.13B Forward P/E9.92 EPS next Y6.44 Insider Trans-8.58% Shs Float1.59B Perf Month-1.63%
Income5.95B PEG1.29 EPS next Q1.26 Inst Own69.40% Short Float2.00% Perf Quarter5.40%
Sales25.64B P/S4.02 EPS this Y16.20% Inst Trans0.01% Short Ratio5.06 Perf Half Y5.98%
Book/sh2.87 P/B22.24 EPS next Y17.04% ROA9.40% Target Price71.22 Perf Year8.00%
Cash/sh3.97 P/C16.06 EPS next 5Y13.52% ROE111.30% 52W Range53.97 - 66.17 Perf YTD3.97%
Dividend2.56 P/FCF36.25 EPS past 5Y10.90% ROI18.00% 52W High-1.99% Beta1.54
Dividend %4.01% Quick Ratio1.50 Sales past 5Y8.00% Gross Margin77.30% 52W Low20.15% ATR0.77
Employees30000 Current Ratio1.70 Sales Q/Q6.20% Oper. Margin36.60% RSI (14)59.93 Volatility1.24% 1.16%
OptionableYes Debt/Eq7.95 EPS Q/Q-7.30% Profit Margin23.20% Rel Volume0.64 Prev Close63.82
ShortableYes LT Debt/Eq7.86 EarningsApr 27 BMO Payout62.10% Avg Volume6.29M Price64.85
Recom2.40 SMA200.64% SMA502.22% SMA2004.94% Volume3,274,091 Change1.61%
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Apr-23-17 03:02PM  3 Dividend Stocks That Investors Should Love Motley Fool
Apr-22-17 09:48AM  Better Buy: AbbVie Inc. vs. Pfizer Motley Fool
Apr-21-17 06:49PM  Cramer's lightning round: This drug stock is simply not good enough for your portfolio CNBC
11:25AM  AbbVie (ABBV) Presents Positive Data on HCV Combination Drug Zacks
09:57AM  What's in Store for AbbVie (ABBV) this Earnings Season? Zacks
08:15AM  Blog Coverage AbbVie's HCV Regimen Achieves 99% Cure Rate in Phase III Study Accesswire
08:00AM  AbbVie to Present at the Deutsche Bank 42nd Annual Health Care Conference PR Newswire
01:00AM  Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C PR Newswire
Apr-20-17 02:46PM  AbbVie, Inc. Value Analysis (NYSE:ABBV) : April 20, 2017 Capital Cube
02:42PM  Failure Of Abbvie's Cancer Drug Hasn't Hurt The Stock Barrons.com
01:21PM  AbbVie's PARP Inhibitor Comes Up Empty Motley Fool
09:53AM  AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies Zacks
07:30AM  AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis PR Newswire
Apr-19-17 07:13PM  AbbVie cancer drug fails two late-stage trials Reuters
06:17PM  AbbVie cancer drug fails two late-stage trials Reuters
08:31AM  AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : April 19, 2017 Capital Cube
06:29AM  Top 4 Medicinal Marijuana Stocks to Watch for 2017 Investopedia
Apr-18-17 04:01PM  Dow's Johnson & Johnson Highlights 'Multiple Issues' For Drugs, Biotechs Investor's Business Daily
03:14PM  Is AbbVie a Great Dividend Stock for Your Portfolio? Motley Fool
01:34PM  The Better Big Pharma Stock: AbbVie or Gilead? GuruFocus.com
11:41AM  High-Yield Healthcare Investments You Can Buy Right Now Motley Fool
Apr-17-17 04:13PM  Can Lilly Survive Rheumatoid Arthritis Flop With Breast Cancer Drug? Investor's Business Daily
11:12AM  AbbVie, Inc. : ABBV-US: Dividend Analysis : April 13th, 2017 (record date) : By the numbers : April 17, 2017 Capital Cube
09:40AM  Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain Motley Fool
Apr-15-17 12:23AM  [$$] As Drug Prices Fall, These Stocks Could Rise Barrons.com
Apr-14-17 12:35PM  ABB Stock Trades Ex-Dividend Tuesday Investopedia
08:04AM  AbbVie Inc.: The Bear Case From a Bull Motley Fool
Apr-10-17 10:48AM  AbbVie's Elagolix Meets Primary Endpoint in Phase II Study Zacks
Apr-09-17 07:22AM  5 Pharmaceutical Stocks With the Most Reliable Dividends Motley Fool
Apr-08-17 06:41AM  3 Cheap High-Yield Dividend Stocks to Grow Your Retirement Portfolio Motley Fool
Apr-07-17 09:56AM  AbbVie Stock Trades Ex-Dividend Tuesday Investopedia
08:00AM  AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids PR Newswire
Apr-06-17 10:48AM  3 Top Big Pharma Stocks to Buy Now Motley Fool
08:00AM  AbbVie to Host First-Quarter Earnings Conference Call PR Newswire
Apr-05-17 04:21PM  Better Buy: AbbVie Inc. vs. GlaxoSmithKline Motley Fool
01:20PM  FDA Grants AbbVie Review for Imbruvica GuruFocus.com
11:17AM  AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA Zacks
07:36AM  Must-Know Corporate and Pipeline Developments for Pfizer Market Realist
Apr-04-17 05:40PM  Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market TheStreet.com
07:00AM  AbbVie Announces Ibrutinib (IMBRUVICA®) Supplemental New Drug Application for Previously Treated Chronic Graft-Versus-Host-Disease (cGVHD) Accepted for Review by U.S. FDA PR Newswire
Mar-31-17 08:41AM  AbbVie's (ABBV) Humira Drug Label Update Approved by FDA Zacks
Mar-30-17 07:37AM  A Look Back at Eli Lillys 2016 Revenue Trends
07:00AM  U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA® (adalimumab) Prescribing Information PR Newswire
Mar-29-17 12:03PM  The Most Undervalued Sectors in the Market Today at Motley Fool
10:36AM  Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe
09:06AM  Which Segments Will Drive the Most Growth for Novartiss Cosentyx?
08:02AM  How AbbVie Is Attacking Tumors at Their Roots Motley Fool
Mar-28-17 09:08PM  [$$] Vertex Pharmaceuticals hails new cystic fibrosis drug Financial Times
05:43PM  Vertex Next-Gen Cystic Fibrosis Drug Passes Key Efficacy, Safety Hurdle
09:00AM  Cannabis Drug Marinol To Get Reboot In Chewing Gum at Forbes
08:00AM  AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program PR Newswire
07:36AM  How Decline in Remicade Is Affecting Mercks Immunology Revenues
07:03AM  3 Things You Probably Didn't Know About AbbVie Inc. at Motley Fool
Mar-27-17 05:49PM  Amgen's Humira Biosimilar Approved in Europe
01:32PM  Shire: Can It Pay Down Debt? at Barrons.com
08:42AM  5 Stocks With Ridiculously Fast-Growing Dividends at Motley Fool
Mar-26-17 11:01AM  3 Great Stocks to Buy in a Market Pullback at Motley Fool
Mar-25-17 02:01PM  Can You Guess Which Drugmaker Has the Most Debt? (Hint: It's Not Valeant) at Motley Fool
10:15AM  Bernie Sanders thinks this $89,000-a-year drug should be $1,000 a year at MarketWatch
Mar-24-17 11:27AM  Amgen's (AMGN) Humira Biosimilar Receives Approval in EU
Mar-23-17 07:45AM  Julianne Hough Empowers Women to "Get in the Know" About Endometriosis PR Newswire
12:51AM  [$$] Rare Discovery: A Value in the Biotech World at The Wall Street Journal
Mar-22-17 05:22PM  Galapagos Begins Cystis Fibrosis Treatment Study
01:39PM  AbbVie upgraded by Societe Generale
01:12PM  [$$] Rare Discovery: A Value in the Biotech World at The Wall Street Journal
08:15AM  Blog Coverage Eli Lilly Announced Positive Results from Breast Cancer Drug Combination Study Accesswire
Mar-21-17 07:51AM  Novartis Cosentyx Shows Psoriasis Modification Potential (NVS, DERM) at Investopedia
07:00AM  Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks at Morningstar
Mar-20-17 07:18PM  [$$] New Enterprise Associates Joins SetPoint Medical Syndicate at The Wall Street Journal
11:55AM  Forbes: Eight of the worlds billionaires call Tampa Bay home at bizjournals.com
09:35AM  Update in Lawsuit for Investors in NYSE: ABBV Shares Against AbbVie Inc. Announced by Shareholders Foundation Accesswire
Mar-16-17 10:49AM  Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China
08:46AM  Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data
Mar-15-17 05:43PM  AbbVie's Hepatitis C Treatment Under Priority Review in Japan
09:24AM  3 Stocks to Add to Your Social Security Income at Motley Fool
Mar-14-17 04:46PM  AbbVie Receives An Upgrade From Vetr
08:00AM  AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C PR Newswire
07:02AM  3 High-Yield Investments in Healthcare at Motley Fool
Mar-13-17 06:50PM  Cramer's Lightning Round: The price to strike with Exxon this week at CNBC
05:16PM  Goldman Sachs Adds AbbVie to Conviction List
08:41AM  The 19 Best-Selling Prescription Drugs of All-Time at Motley Fool
Mar-11-17 11:41AM  Which Biotech Is the Best Dividend Stock? at Motley Fool
Mar-10-17 04:40PM  AbbVie Outperforms Drug Stocks On $20.5 Billion Growth View
04:31PM  US STOCKS-Wall St ends up; jobs data points to economic strength
04:02PM  AbbVie Price Target Hiked, Marathon Oil Rated Outperform
01:12PM  AbbVie Stock Upgraded: What You Need to Know at Motley Fool
01:03PM  US STOCKS-Wall St trims gains as jobs data paves Fed path to hike rates Reuters
12:45PM  These 2 Dividend Aristocrats Are Ridiculously Cheap at Motley Fool
12:20PM  AbbVie: Be More Like Google? at Barrons.com
11:26AM  US STOCKS-Wall St rises as robust jobs report lifts mood Reuters
10:21AM  AbbVie, Inc. :ABBV-US: Earnings Analysis: Q4, 2016 By the Numbers : March 10, 2017
08:45AM  Top Analyst Upgrades and Downgrades: AbbVie, KLA-Tencor, Marathon Oil, Verifone and Many More
Mar-09-17 04:55PM  Will Merck, Glaxo Undercut Gilead's Next 'Mount Everest' Drug?
09:21AM  AbbVie at the Cowen Healthcare Conference: 4 Things You'll Want to Know at Motley Fool
06:04AM  Germany's Merck well advanced in talks to sell biosimilars unit
Mar-08-17 05:15PM  AbbVie Is a Screaming Dividend Growth Buy... Here's Why
03:38PM  Billionaire Investor Is Concentrating on Small-Caps and Pharma
12:29PM  Results of Johnson & Johnson's Psoriasis Clinical Trials Impressive
Mar-07-17 04:21PM  Novartis (NVS) Reports Positive Data on Biosimilar Humira
10:05AM  Jefferies Strongly Reiterates Top Pick Call On AbbVie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; and M2Gen. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AbbVie Inc.10% OwnerMar 28Sale22.50450,00010,125,0001,190,473Mar 30 05:48 PM
Schumacher Laura JExecutive Vice PresidentMar 10Sale65.2640,0002,610,257107,825Mar 10 05:22 PM
Michael Robert A.VP, ControllerMar 10Sale65.295,132335,06816,706Mar 10 05:22 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 10Sale65.2922,4511,465,82626,078Mar 10 05:21 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Option Exercise27.9572,0162,012,610422,763Mar 10 05:20 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Sale64.2572,0164,627,028350,747Mar 10 05:20 PM
HURWICH THOMAS A.VP, ControllerFeb 28Sale61.892,311143,03167,276Mar 02 06:12 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 02Option Exercise27.292,40065,4965,431Feb 03 05:21 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Option Exercise27.296,600180,114178,970Dec 02 05:08 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Sale59.196,600390,654172,370Dec 02 05:08 PM
HURWICH THOMAS A.VP, ControllerNov 16Option Exercise28.863,10089,47564,549Nov 18 05:39 PM
HURWICH THOMAS A.VP, ControllerNov 16Sale62.003,100192,20061,449Nov 18 05:39 PM
Schumacher Laura JExecutive Vice PresidentSep 07Sale65.0050,0003,250,000144,138Sep 09 05:38 PM
Schumacher Laura JExecutive Vice PresidentJun 24Option Exercise27.62186,1065,140,971380,244Jun 28 05:47 PM
Schumacher Laura JExecutive Vice PresidentJun 24Sale60.03186,10611,171,173194,138Jun 28 05:47 PM
GONZALEZ RICHARD AChairman of the Board and CEOJun 02Sale63.82285,95318,249,712338,421Jun 03 05:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 11Sale63.8039,0002,488,200338,421May 13 05:11 PM
HURWICH THOMAS A.VP, ControllerMay 10Option Exercise27.296,000163,74068,204May 12 05:44 PM
ALBAN CARLOSEVP, Commercial OperationsMay 10Sale63.5247,4383,013,262149,444May 12 05:39 PM
HURWICH THOMAS A.VP, ControllerMay 10Sale63.596,000381,54162,204May 12 05:44 PM